Digital tools in Huntington’s disease clinical trials

Patrick Weydt, MD, PhD, University of Bonn Medical Center, Bonn, Germany, discusses the promise of wearable devices and digital technology as innovative tools to aid disease monitoring and support therapeutic development in Huntington’s disease (HD). Symptoms of HD can vary significantly and evolve over time. Using a tool that could not only assess HD manifestations over a long period of time, but also capture day-to-day variability, could provide valuable information in clinical trial settings. Additionally, quantitative technologies have the potential to detect and monitor very subtle motor and cognitive alterations, even in pre-manifest HD. Gait and balance, cognition, sleep characteristics, tremor, motor activity, mood, and socialization are some of the disease characteristics that can be assessed with digital sensors. The lack of biomarkers in the HD space means it can be challenging to capture therapeutic effects. Incorporating digital tools as endpoints in clinical trials is a promising future avenue. This interview took place during the European Huntington's Disease Network 2022 Plenary Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Be the first to comment